Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04625725 · ClinicalTrials.gov registry record · Phase 3
Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 5,197
- Enrollment target
NCT04625725: Completed Phase 3 study, sponsored by AstraZeneca.
NCT04625725 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 5,197 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (573% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04625725, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 5,197 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.
Primary Outcome
To estimate the efficacy of a single IM dose of AZD7442 compared to placebo for the prevention of COVID-19 prior to Day 183. Planned to be evaluated through Day 183, however, the number of events required for the primary endpoint was achieved 165 days after the study start date which is displayed in the primary efficacy row below. Final analysis is final data from the study based on the pre-planned 183 days of follow up for this endpoint.
Interventions
- DRUG Placebo
- DRUG AZD7442
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,197 participants |
| Start Date | 2020-11-21 |
| Est. Completion | 2023-12-08 |
| Phase | Phase 3 |
What the finished NCT04625725 record still lists
NCT04625725 is an interventional study that assigns participants to a tested intervention. Its 5,197 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (573% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04625725 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04625725 about?
NCT04625725 is a clinical study titled "Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.". This study will assess the safety and efficacy of a single dose of AZD7442(× 2 IM injections) compared to placebo for the prevention of COVID-19.
What is the current status of trial NCT04625725?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 5,197 participants. The study started on 2020-11-21. Estimated completion is 2023-12-08.
What interventions are being tested in trial NCT04625725?
The interventions under investigation include: Placebo (DRUG), AZD7442 (DRUG).
Who is sponsoring clinical trial NCT04625725?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04625725's enrollment target sits among peer trials
5,197 47th of 2000 higher than 1,954 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05989308 · 5,200 participants · NA
MyChart Proxy Outreach to Parents (MyPOP)
- NCT06008197 · 5,200 participants · Phase 3
A Study to Determine the Efficacy and Safety of Finerenone on Morbidity and Mortality Among Hospitalized Heart Failure Patients
- NCT05135403 · 5,179 participants
ASSURE WCD Clinical Evaluation - Post Approval Study (ACE-PAS)
- NCT06506344 · 5,250 participants · NA
Syncing Screening and Services for Suicide Prevention Across Health and Justice Systems
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI